Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Summary

The bill changes the rules for Minnesota’s Formulary Committee so that members who have a potential conflict of interest can continue to take part in committee communications and discussions, though they must recuse from voting on those matters. It also directs the commissioner of human services to set up a public comment system for the committee’s recommendations and obligates the committee to obtain input from the Minnesota Rare Disease Advisory Council on orphan‑drug and prior‑authorization issues. These changes aim to increase transparency while still allowing expert input.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share